You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Cancer patients with BRCA1 or BRCA2 genetic mutations appear to have strikingly different response patterns to immune checkpoint inhibitors, according to a Nature Cancer study published on Monday.
Premium Access gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.